Pfizer Inc Sample Contracts

EXHIBIT 99.2 AGREEMENT AND PLAN OF MERGER
Agreement and Plan of Merger • December 23rd, 2003 • Pfizer Inc • Pharmaceutical preparations • Delaware
AutoNDA by SimpleDocs
AMONG PFIZER INC.,
Agreement and Plan of Merger • July 16th, 2002 • Pfizer Inc • Pharmaceutical preparations • New York
Pfizer Inc.
Underwriting Agreement • October 20th, 2000 • Pfizer Inc • Pharmaceutical preparations • New York
AGREEMENT AND PLAN OF MERGER Dated as of February 6, 2000 among PFIZER INC., SEMINOLE ACQUISITION SUB CORP. and WARNER-LAMBERT COMPANY
Agreement and Plan of Merger • February 18th, 2000 • Pfizer Inc • Pharmaceutical preparations • Delaware
EXHIBIT 10.1 U.S. $22,500,000,000 364-DAY BRIDGE TERM LOAN CREDIT AGREEMENT Dated as of March 12, 2009
Credit Agreement • March 12th, 2009 • Pfizer Inc • Pharmaceutical preparations • New York
AMENDMENT TO AGREEMENT AND PLAN OF MERGER BY AND AMONG PFIZER INC., ENZO ACQUISITION CORP. AND ESPERION THERAPEUTICS, INC.
Agreement and Plan of Merger • January 23rd, 2004 • Pfizer Inc • Pharmaceutical preparations • Delaware
------------------------------------------------------------------------------- - SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------ FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS...
Pfizer Inc • March 29th, 1996 • Pharmaceutical preparations

PFIZER SAVINGS AND INVESTMENT PLAN FOR EMPLOYEES RESIDENT IN PUERTO RICO STATEMENT OF NET ASSETS AVAILABLE FOR PLAN BENEFITS DECEMBER 31, 1995

PFIZER INC. to
Pfizer Inc • January 30th, 2001 • Pharmaceutical preparations • New York
Pfizer Inc. Debt Securities Underwriting Agreement
Underwriting Agreement • June 3rd, 2016 • Pfizer Inc • Pharmaceutical preparations • New York

From time to time Pfizer Inc., a Delaware corporation (the “Company”), proposes to enter into one or more Pricing Agreements (each a “Pricing Agreement”) in the form of Annex I hereto, with such additions and deletions as the parties thereto may determine, and subject to the terms and conditions stated herein and therein, to issue and sell to the firms named in Schedule I to the applicable Pricing Agreement (such firms constituting the “Underwriters” with respect to such Pricing Agreement and the securities specified therein) certain of its debt securities (the “Securities”) specified in Schedule II to such Pricing Agreement (with respect to such Pricing Agreement, the “Designated Securities”).

PFIZER INVESTMENT ENTERPRISES PTE. LTD., as Issuer PFIZER INC., as Parent Guarantor and THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of May 19, 2023 DEBT SECURITIES
Indenture • May 19th, 2023 • Pfizer Inc • Pharmaceutical preparations • New York

INDENTURE, dated as of May 19, 2023, among PFIZER INVESTMENT ENTERPRISES PTE. LTD., a private company limited by shares incorporated under the laws of the Republic of Singapore (the “Issuer”), PFIZER INC., a Delaware corporation (the “Parent Guarantor”), and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee (the “Trustee”).

AGREEMENT AND PLAN OF MERGER among: MEDIVATION, INC. a Delaware corporation; PFIZER INC., a Delaware corporation; and MONTREAL, INC., a Delaware corporation Dated as of August 20, 2016
Agreement and Plan of Merger • August 22nd, 2016 • Pfizer Inc • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of August 20, 2016, by and among Pfizer Inc., a Delaware corporation (“Parent”); Montreal, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”); and Medivation, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

PFIZER INC. TO
Pfizer Inc • October 20th, 2000 • Pharmaceutical preparations • New York
AGREEMENT ---------
Pfizer Inc • March 26th, 1998 • Pharmaceutical preparations • Delaware
Pfizer Inc. Debt Securities Underwriting Agreement
Underwriting Agreement • August 18th, 2021 • Pfizer Inc • Pharmaceutical preparations • New York

From time to time Pfizer Inc., a Delaware corporation (the “Company”), proposes to enter into one or more Pricing Agreements (each a “Pricing Agreement”) in the form of Annex I hereto, with such additions and deletions as the parties thereto may determine, and subject to the terms and conditions stated herein and therein, to issue and sell to the firms named in Schedule I to the applicable Pricing Agreement (such firms constituting the “Underwriters” with respect to such Pricing Agreement and the securities specified therein) certain of its debt securities (the “Securities”) specified in Schedule II to such Pricing Agreement (with respect to such Pricing Agreement, the “Designated Securities”).

AGREEMENT AND PLAN OF MERGER by and among PFIZER INC., ARIS MERGER SUB, INC. and SEAGEN INC., Dated as of MARCH 12, 2023
Agreement and Plan of Merger • March 13th, 2023 • Pfizer Inc • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 12, 2023, is by and among Pfizer Inc., a Delaware corporation (“Parent”), Aris Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Seagen Inc., a Delaware corporation (the “Company”).

PFIZER INC. AT $35.00 PER SHARE
Offer to Purchase • January 7th, 2004 • Pfizer Inc • Pharmaceutical preparations
SUBSCRIPTION AGREEMENT
Subscription Agreement • November 6th, 2020 • Pfizer Inc • Pharmaceutical preparations

This Subscription Agreement (this “Subscription Agreement” is being entered into as of the date set forth on the signature page hereto, by and between ARYA Sciences Acquisition Corp II, a Cayman Islands exempted company, which shall be domesticated as a Delaware corporation prior to the closing of the Transaction (as defined herein) (“ARYA”). and the undersigned subscriber (the “Investor”), in connection with the Business Combination Agreement, dated as of the date hereof (as may be amended, supplemented or otherwise modified from time to time, the “Transaction Agreement”), by and among ARYA, Cerevel Therapeutics, Inc., a Delaware corporation (the “Company”). Cassidy Merger Sub 1, Inc., a Delaware corporation (“Cassidy Merger Sub 1”). pursuant to which, among other things, Cassidy Merger Sub 1 will merge with and into the Company, with the Company as the surviving company in the merger and, after giving effect to such merger, becoming a wholly-owned subsidiary of ARYA, on the terms and

STOCK AND ASSET PURCHASE AGREEMENT by and among PFIZER INC.,
Stock and Asset Purchase Agreement • February 28th, 2019 • Pfizer Inc • Pharmaceutical preparations • New York

This STOCK AND ASSET PURCHASE AGREEMENT, dated as of December 19, 2018 (this “Agreement”), is by and among Pfizer Inc., a Delaware corporation (“Seller Parent”), GlaxoSmithKline Plc, a public limited company incorporated under the laws of England (“Purchaser Parent”, and together with Seller Parent, the “Parents”), and GlaxoSmithKline Consumer Healthcare Holdings Limited, a company incorporated under the laws of England (“Purchaser,” and together with the Parents, the “Parties”).

Agreement and Plan of Merger dated as of February 20, 2008 among Pfizer Inc., Explorer Acquisition Corp. and Encysive Pharmaceuticals Inc.
Agreement and Plan of Merger • March 4th, 2008 • Pfizer Inc • Pharmaceutical preparations • Delaware

Agreement and Plan of Merger (this “Agreement”), dated as of February 20, 2008, among Pfizer Inc., a Delaware corporation (“Parent”), Explorer Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and Encysive Pharmaceuticals Inc., a Delaware corporation (the “Company”).

AutoNDA by SimpleDocs
to
Stock and Asset Purchase Agreement • March 26th, 1999 • Pfizer Inc • Pharmaceutical preparations • New York
AMENDMENT NO. 3 TO THE SEPARATION AND DISTRIBUTION AGREEMENT
Separation and Distribution Agreement • November 5th, 2020 • Pfizer Inc • Pharmaceutical preparations

This Amendment No. 3 (this “Amendment”) to the Separation and Distribution Agreement, dated as of July 29, 2019, as amended (the “Agreement”), is made as of September 18, 2020 by and between Pfizer Inc., a Delaware corporation (“Pluto”) and Upjohn Inc., a Delaware corporation and wholly owned Subsidiary of Pluto (“Spinco”). Each of the foregoing parties is referred to herein as a “Party” and collectively as the “Parties.”

TIME SHARING AGREEMENT
Time Sharing Agreement • August 6th, 2020 • Pfizer Inc • Pharmaceutical preparations • New York

This Time Sharing Agreement (this “Agreement”) is dated this 9th day of July, 2020, by and between Pfizer Inc., a Delaware corporation (the “Company”) and Albert Bourla, an individual (“Lessee”).

TERMINATION AGREEMENT
Termination Agreement • April 6th, 2016 • Pfizer Inc • Pharmaceutical preparations • Delaware

This TERMINATION AGREEMENT (this “Agreement”), dated as of April 6, 2016, is by and among Pfizer Inc., a Delaware corporation (the “Company”), Allergan plc, an Irish public limited company (“Parent”), Watson Merger Sub Inc., a Delaware corporation and a direct wholly owned Subsidiary of Parent (“Merger Sub”), and Allergan Medical GmbH (f/k/a Allergan Medical S.À.R.L.), a wholly owned Subsidiary of Parent (“Medical”) (each, a “Party” and collectively, the “Parties”).

CONFIDENTIALITY AGREEMENT April 19, 2016
Confidentiality Agreement • May 26th, 2016 • Pfizer Inc • Pharmaceutical preparations • Delaware

In connection with your consideration of a possible transaction involving Anacor Pharmaceuticals, Inc. (the “Company”) and Pfizer Inc. (“Pfizer”) (the “Transaction”), it is expected that each party may furnish or otherwise make available (the “Disclosing Party”) certain information regarding the Disclosing Party’s business, operations and affairs to the other party (the “Receiving Party”). Such information (whether oral, written, electronic or otherwise), regardless of the form in which it is provided or maintained and whether prepared by the Disclosing Party, its Representatives (as defined below) or otherwise and whether provided on or after the date hereof, together with those portions of any notes, analyses, compilations, studies, interpretations or other documents prepared by the Receiving Party or any of the Receiving Party’s Representatives that contain or otherwise reflect such information is hereinafter referred to as “Confidential Information,” except that “Confidential Infor

VOTING AGREEMENT
Voting Agreement • March 13th, 2023 • Pfizer Inc • Pharmaceutical preparations • Delaware

This VOTING AGREEMENT (this “Agreement”), dated as of March 12, 2023, is by and among (i) Pfizer Inc., a Delaware corporation (“Parent”), (ii) Seagen Inc., a Delaware corporation (the “Company”), and (iii) Baker Bros. Advisors LP (the “Advisor”), on behalf of itself and the persons listed on Schedule A hereto in their capacity as record or beneficial owners of Common Shares (as defined below) (each, a “Stockholder” and, collectively, the “Stockholders”). Each of Parent, the Company and the Advisor are sometimes referred to as a “Party.”

AMENDMENT NO. 1 TO THE SEPARATION AND DISTRIBUTION AGREEMENT
Separation and Distribution Agreement • February 27th, 2020 • Pfizer Inc • Pharmaceutical preparations

This Amendment No. 1 (this “Amendment”) to the Separation and Distribution Agreement, dated as of July 29, 2019 (the “Agreement”), is made as of February 18, 2020, by and between Pfizer Inc., a Delaware corporation (“Pfizer”), and Upjohn Inc., a Delaware corporation and wholly owned Subsidiary of Pfizer (“Upjohn”, and together with Pfizer, the “Parties”, and each, a “Party”).

SEPARATION AND DISTRIBUTION AGREEMENT by and between PFIZER INC. and UPJOHN INC. Dated as of July 29, 2019
Separation and Distribution Agreement • July 29th, 2019 • Pfizer Inc • Pharmaceutical preparations • Delaware

This SEPARATION AND DISTRIBUTION AGREEMENT, dated as of July 29, 2019, is by and between Pfizer Inc., a Delaware corporation (“Pluto”), and Upjohn Inc., a Delaware corporation (“Spinco”). Capitalized terms used herein and not otherwise defined shall have the respective meanings assigned to them in Article I hereof.

Contract
Eighth Supplemental Indenture • November 3rd, 2009 • Pfizer Inc • Pharmaceutical preparations • New York

EIGHTH SUPPLEMENTAL INDENTURE, dated as of October 30, 2009 (this “Eighth Supplemental Indenture”), between WYETH, a Delaware corporation (as successor to American Home Products Corporation) (the “Issuer”), Pfizer Inc., a Delaware corporation (“Pfizer”) and THE BANK OF NEW YORK MELLON (as successor to JPMORGAN CHASE BANK), a banking corporation duly organized and existing under the laws of the State of New York, as trustee (the “Trustee”).

AGREEMENT AND PLAN OF MERGER AMONG PFIZER INC, PERKINS HOLDING COMPANY AND HOSPIRA, INC. Dated as of February 5, 2015
Agreement and Plan of Merger • February 6th, 2015 • Pfizer Inc • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of February 5, 2015, is among Pfizer Inc. (“Parent”), a Delaware corporation, Perkins Holding Company (“Sub”), a Delaware corporation and a wholly owned subsidiary of Parent, and Hospira, Inc. (the “Company”), a Delaware corporation.

BUSINESS COMBINATION AGREEMENT by and among PFIZER INC., UPJOHN INC., UTAH ACQUISITION SUB INC., MYLAN N.V., MYLAN I B.V. and MYLAN II B.V. Dated as of July 29, 2019
Business Combination Agreement • July 29th, 2019 • Pfizer Inc • Pharmaceutical preparations • Utah

This BUSINESS COMBINATION AGREEMENT (this “Agreement”) dated as of July 29, 2019, is by and among Pfizer Inc., a Delaware corporation (“Pluto”), Upjohn Inc., a Delaware corporation and wholly owned Subsidiary of Pluto (“Spinco”), Utah Acquisition Sub Inc., a Delaware corporation and an indirectly wholly owned Subsidiary of Spinco (“Spinco Sub” and together with Spinco, the “Spinco Parties”), Mylan N.V., a public company with limited liability incorporated under the laws of the Netherlands (“Utah”), Mylan I B.V., a company incorporated under the laws of the Netherlands and a direct wholly owned subsidiary of Utah (“Utah Newco”), Mylan II B.V., a company incorporated under the laws of the Netherlands and a direct wholly owned subsidiary of Utah Newco (“Utah Newco Sub” and together with Utah and Utah Newco, the “Utah Parties”). Each of the foregoing parties is referred to herein as a “Party” and collectively as the “Parties.”

Time is Money Join Law Insider Premium to draft better contracts faster.